Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients

Table 3 Main clinical findings after 6 years of follow up

Variables	Tol group	CNI group	MMF group	P value
	6 yr	6 yr	6 yr	Tol vs CNII	Tol vs MMFF
Patients (n)	10	21	15
Death (n)	0	1	0
ALT (IU/L)	71.1 ± 54.2	53.9 ± 33.7	59.4 ± 45.6	NS	NS
Creatinina	1.3 ± 0.5	1.28 ± 0.5	1.7 ± 1.6	NS	NS
Cholesterol	153.6 ± 55.2	161.9 ± 43.2	155.9 ± 30	NS	NS
Triglycerides	130.6 ± 64.1	125.4 ± 45.6	121.8 ± 39.8	NS	NS
HCV-RNA > 500000 IU/mL	70	42.8	46.6	NS	NS
Recurrent infections1	0	42.8	40	0.029	0.019
Cardiovascular diseases	50	23	6.6	NS	NS
Diabetes	30	33	27	NS	NS
Dyslipidemia	50	19	13	NS	NS
FPR	-0.019	0.32	0.02	0.02	NS

¹Urinary and bronchopulmonary infections. FPR: Fibrosis progression rate; ALT: Alanine aminotransferase; HCV: Hepatitis C virus; CNI: Calcineurin inhibitors; MMF: Mycophenolate; NS: Not significant.